601 related articles for article (PubMed ID: 27550371)
1. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
Lao KS; He Y; Wong IC; Besag FM; Chan EW
CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
[TBL] [Abstract][Full Text] [Related]
2. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Cariprazine in Acute Management of Psychiatric Disorders: a Meta-Analysis of Randomized Controlled Trials.
Cooper H; Mishriky R; Reyad AA
Psychiatr Danub; 2020; 32(1):36-45. PubMed ID: 32303028
[TBL] [Abstract][Full Text] [Related]
4. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies.
Earley W; Durgam S; Lu K; Debelle M; Laszlovszky I; Vieta E; Yatham LN
J Affect Disord; 2017 Jun; 215():205-212. PubMed ID: 28343051
[TBL] [Abstract][Full Text] [Related]
6. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
[TBL] [Abstract][Full Text] [Related]
7. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.
Ketter TA; Sachs GS; Durgam S; Lu K; Starace A; Laszlovszky I; Németh G
J Affect Disord; 2018 Jan; 225():350-356. PubMed ID: 28843918
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
[TBL] [Abstract][Full Text] [Related]
9. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.
Edinoff A; Ruoff MT; Ghaffar YT; Rezayev A; Jani D; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2020 Sep; 50(4):83-117. PubMed ID: 33012874
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
[TBL] [Abstract][Full Text] [Related]
11. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
Citrome L
Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832
[TBL] [Abstract][Full Text] [Related]
12. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.
Sachs GS; Greenberg WM; Starace A; Lu K; Ruth A; Laszlovszky I; Németh G; Durgam S
J Affect Disord; 2015 Mar; 174():296-302. PubMed ID: 25532076
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
14. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
Citrome L
Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.
Cutler AJ; Durgam S; Wang Y; Migliore R; Lu K; Laszlovszky I; Németh G
CNS Spectr; 2018 Feb; 23(1):39-50. PubMed ID: 28478771
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of cariprazine in the treatment of bipolar disorder.
Saraf G; Pinto JV; Yatham LN
Expert Opin Pharmacother; 2019 Dec; 20(17):2063-2072. PubMed ID: 31644326
[No Abstract] [Full Text] [Related]
19. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.
Durgam S; Greenberg WM; Li D; Lu K; Laszlovszky I; Nemeth G; Migliore R; Volk S
Psychopharmacology (Berl); 2017 Jan; 234(2):199-209. PubMed ID: 27807604
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study.
Earley WR; Burgess MV; Khan B; Rekeda L; Suppes T; Tohen M; Calabrese JR
Bipolar Disord; 2020 Jun; 22(4):372-384. PubMed ID: 31628698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
